Pharmaceutical - Pharmaceutical, Neurological

Filter

Popular Filters

1 to 25 of 779 results

Supreme Court reverses Federal Circuit Court judgment on '808 patent in Teva's Copaxone

Supreme Court reverses Federal Circuit Court judgment on '808 patent in Teva's Copaxone

21-01-2015

The US Supreme Court has reversed the Federal Circuit Court’s judgment on Israel-based Teva Pharmaceutical…

CopaxoneLegalNeurologicalPharmaceuticalTevaUSA

US FTC approves final order preserving in nicotine patches market competition

US FTC approves final order preserving in nicotine patches market competition

21-01-2015

Following a public comment period, the USA’s Federal Trade Commission has approved a final order settling…

GlaxoSmithKlineHabitrolMergers & AcquisitionsNeurologicalNovartisPharmaceuticalRegulationUSA

Eisai launches epilepsy treatment Exalief in Russia

Eisai launches epilepsy treatment Exalief in Russia

20-01-2015

Japanese drug major Eisai has announced that epilepsy drug Exalief (eslicarbazepine acetate) will soon…

EisaiExaliefMarkets & MarketingNeurologicalPharmaceuticalRussia

FDA approves Fresenius Kabi’s neostigmine methylsulfate injection

FDA approves Fresenius Kabi’s neostigmine methylsulfate injection

20-01-2015

Fresenius Kabi, a unit of the Germany-headquartered Fresenius Group, has received approval from the US…

FreseniusFresenius Kabineostigmine methylsulfateNeurologicalPharmaceuticalRegulationUSA

Gedeon Richter and Actavis announce positive results from Phase III trial of cariprazine in schizophrenia

Gedeon Richter and Actavis announce positive results from Phase III trial of cariprazine in schizophrenia

20-01-2015

Hungary’s largest pharma company Gedeon Richter and Ireland-headquartered generics major Actavis have…

ActaviscariprazineGedeon RichterNeurologicalPharmaceuticalResearch

Addex Therapeutics teams up with Dystonia Medical Research Foundation on dipraglurant

Addex Therapeutics teams up with Dystonia Medical Research Foundation on dipraglurant

19-01-2015

Swiss pharma company Addex Therapeutics is to enter into a collaboration with the Dystonia Medical Research…

Addex PharmadipraglurantNeurologicalPharmaceuticalResearch

UCB signs up to $480 million global collaboration with Neuropore on PD

18-01-2015

Neuropore Therapies, a wholly-owned US subsidiary of Austria’s Ever Neuro Pharma, has entered into…

Ever Neuro PharmaGlobalLicensingNeurologicalNeuropore TherapiesNPT200-11PharmaceuticalResearchUCB

Depomed pays over $1 billion for US rights to Janssen’s Nucynta franchise

Depomed pays over $1 billion for US rights to Janssen’s Nucynta franchise

16-01-2015

US specialty drugmaker Depomed has entered into a definitive agreement to acquire the US rights to the…

DepomedGrunenthalJanssenJohnson & JohnsonLicensingNeurologicalNucyntaPharmaceuticalUSA

Boehringer Ingelheim, Janssen and Novartis among partners teaming up for Alzheimer's research

Boehringer Ingelheim, Janssen and Novartis among partners teaming up for Alzheimer's research

15-01-2015

German family-owned drug major Boehringer Ingelheim is one of 35 partners from industry and academia…

AmgenBoehringer IngelheimEuropeJanssenNeurologicalNovartisPharmaceuticalResearch

Sumitomo Dainippon and Sunovion file patent infringement  law suits for Latuda

Sumitomo Dainippon and Sunovion file patent infringement law suits for Latuda

15-01-2015

Japanese pharma company Sumitomo Dainippon and its US subsidiary Sunovion Pharmaceuticals have jointly…

Emcure PharmaceuticalsLatudaLegallurasidoneNeurologicalPharmaceuticalSumitomoSunovion PharmaceuticalsUSA

US FDA approves AbbVie’s Duopa for Parkinson’s disease

US FDA approves AbbVie’s Duopa for Parkinson’s disease

13-01-2015

The US Food and Drug Administration has approved US drugmaker AbbVie’s Duopa (carbidopa and levodopa)…

AbbVieCarbidopa-LevodopaNeurologicalPharmaceuticalRegulationUSA

Esteve could earn $1 billion from pain partnership with Mundipharma and Purdue

Esteve could earn $1 billion from pain partnership with Mundipharma and Purdue

12-01-2015

Swiss drugmaker Mundipharma Laboratories and its independent associated company, Purdue Pharmaceuticals,…

E-52862E-58425Esteve GroupLicensingMundipharmaNeurologicalPharmaceuticalPurdue PharmaResearch

CHMP recommends approval of Newron/Zambon's Xadago for Parkinson's disease

CHMP recommends approval of Newron/Zambon's Xadago for Parkinson's disease

07-01-2015

Italy-based Newron Pharmaceuticals and its partner Zambon have received a recommendation from the Euroean…

ItalyNeurologicalNewron PharmaceuticalsPharmaceuticalRegulationXadagoZambon

Actavis’ Namenda appeal expedited to February

Actavis’ Namenda appeal expedited to February

07-01-2015

Ireland-headquartered generics major Actavis has had its motion to expedite its appeal of a lower court…

ActavisAppellate reviewLawLegalNamendaNeurologicalPharmaceuticalUSA

Monash University to study role of aspirin in prevention of dementia

05-01-2015

The humble aspirin, originally used only as a pain killer but since has been identified as a factor in…

AspirinAustraliaNeurologicalPharmaceuticalResearchUSA

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

05-01-2015

Japanese drug major Eisai has announced a Phase III trial of antiepileptic drug Fycompa (perampanel)…

EisaiFycompaJapanNeurologicalperampanelPharmaceuticalResearch

Hospira gains US FDA backing for non-opioid analgesic Dyloject

Hospira gains US FDA backing for non-opioid analgesic Dyloject

31-12-2014

US injectable drugs and infusion technologies specialist Hospira has received approval from the US Food…

DylojectHospiraNeurologicalPharmaceuticalRegulationUSA

Sumitomo Dainippon’s lurasidone meets primary endpoint in Ph III study

30-12-2014

Japanese drug major Sumitomo Dainippon Pharma has released positive preliminary findings from a Phase…

Dainippon Sumitomo PharmaJapanLatudalurasidoneNeurologicalPharmaceuticalRegulationResearch

Takeda gains approval for Takecab in Japan; files MS drug NDA

Takeda gains approval for Takecab in Japan; files MS drug NDA

29-12-2014

Japan’s largest drugmaker Takeda Pharmaceutical and partner Otsuka Pharmaceuticals have been granted…

Gastro-intestinalsGlatiramer AcetateJapanNeurologicalOtsuka PharmaceuticalsPharmaceuticalRegulationTakecabTakeda PharmaceuticalTeva Pharmaceuticals Industriesvonoprazan

Newron and Zambon re-submit NDA for safinamide following Refusal to File

Newron and Zambon re-submit NDA for safinamide following Refusal to File

29-12-2014

Clinical-stage biopharma company Newron and its commercial development partner, fellow Italy-based pharma…

NeurologicalNewron PharmaPharmaceuticalRegulationsafinamideUSAZambon

FDA backs Actavis’ Namzaric, but issues CRL on nebivolol/valsartan combo

FDA backs Actavis’ Namzaric, but issues CRL on nebivolol/valsartan combo

26-12-2014

The US Food and Drug Administration has approved the New Drug Application for Namzaric (formerly known…

ActavisAdamas PharmaceuticalsCardio-vasculardonepezilMemantine HCLNamzaricnebivololNeurologicalPharmaceuticalRegulationUSAvalsartan

Reckitt Benckiser demerger goes through, creating Indivior as pharma arm

Reckitt Benckiser demerger goes through, creating Indivior as pharma arm

23-12-2014

The UK-based consumer goods giant Reckitt Benckiser Group has demerged what was once its USA-based pharma…

FinancialIndivior PLCMergers & AcquisitionsNeurologicalPharmaceuticalReckitt BenckiserUSA

Vanda and Novartis to settle arbitration, with rights to Fanapt returned

23-12-2014

US biopharma firm Vanda Pharmaceuticals says it has reached a settlement agreement with Swiss drug major…

FanaptLegalLicensingMergers & AcquisitionsNeurologicalNovartisPharmaceuticalVanda Pharmaceuticals

USA files suit against Omnicare for accepting kickbacks from Abbott

23-12-2014

The United States has filed a civil False Claims Act complaint against Omnicare alleging that it solicited…

Abbott LaboratoriesDepakoteLegalMarkets & MarketingNeurologicalOmnicarePharmaceuticalUSA

1 to 25 of 779 results

Back to top